Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
about
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyCIViC databaseImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Overcoming therapeutic resistance in glioblastoma: the way forwardTargeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.History and current state of immunotherapy in glioma and brain metastasis.Actionable molecular biomarkers in primary brain tumors.Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cellsWhen Genome Maintenance Goes Badly Awry.Leveraging premalignant biology for immune-based cancer prevention.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis.Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.SOX2 immunity and tissue resident memory in children and young adults with glioma.Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.Glioblastoma targeted therapy: updated approaches from recent biological insights.Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens.Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Genomic landscape of high-grade meningiomas.Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.Immune Checkpoint Inhibitors in Gliomas.Correlation of immune phenotype with IDH mutation in diffuse glioma.Advances in the molecular genetics of gliomas - implications for classification and therapy.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1.Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.Investigational new drugs for brain cancer.POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologiesRecommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.Immunological effects of chemotherapy and radiotherapy against brain tumors.Novel vaccines for glioblastoma: clinical update and perspective.The Microenvironmental Landscape of Brain Tumors.Unleashing the immune response against childhood solid cancers.
P2860
Q26745516-41A7915B-8419-4355-BFF2-F513D9657F46Q27612411-BCF0C87E-99F8-4AD7-BDDC-1F4B83869175Q28078539-C8CADB29-B172-4FF9-BE30-EF8B96B69D01Q29248396-56C8B090-9F42-4AF3-925B-E4C570EF0BE6Q33276475-EAAA622C-E5D2-4F76-90CA-6CC647602799Q33656811-D4920B98-31DF-4520-A024-01A1E3214C9DQ33772355-824A0BC9-F4C2-4705-BF9F-5F3B34D2A660Q33798642-8166CA76-C9C4-49CF-A71E-F02781BFBAE0Q37138583-8360CF30-9892-41B6-94A1-E310BA6D619AQ37304964-0F6D10C9-B2C4-4783-AF91-89F014DC2383Q37584395-E5C8A430-3C13-4248-AC5D-0C5BA9D6903BQ37619794-037ED1B1-BAD1-4369-9449-50BA3ECCC6E0Q37672257-932EF780-581D-4637-9698-235149EF2D49Q37705031-53357978-9450-4059-B69E-4E8F6D2E6D7AQ37730613-1AE090E1-4F96-4967-978E-79947D742BB6Q38373829-BD244A8C-BFBD-411E-9103-E27E7CE26D90Q38438763-A76EFD2C-FCA9-47E2-9628-D48DBF2B540AQ38597700-A8597CF3-4BBB-4C49-8315-7A39CE45C302Q38626084-B485A803-6EF4-412F-B840-F3FC1F829DE3Q38635512-A7025978-EC82-4A80-B5BE-2DF4CBCD79D2Q38643300-F690B8FD-41EC-4289-928D-32BE875FA0F5Q38676440-A862905A-4070-4965-A2D5-9E1B0D2A2167Q38691679-E12C8C7C-7706-41AD-982F-7B16A4422A8BQ38743793-8795AAFF-327D-4AD0-A7C9-CCFA1C5B3537Q38771020-84BEFB55-ACDD-4488-9F09-1920289B321BQ38777058-C3D704EA-A19E-46C5-81C8-2DD12F9D8ACDQ38789860-5201A246-FFD5-4E99-8F0D-6951A8969C12Q38796220-B8EA1705-E0FB-4D66-829F-F4892752A14CQ38806007-9172D677-B1D7-4C55-8361-FCD2530E9D9EQ38810264-CC359A83-18FE-413B-9DFD-2BDA76B2EA3CQ38819982-2686CF6E-C8E6-43F5-B34E-02F481703B2FQ38832510-C6656378-49E7-478C-B9B8-FF294DD18A06Q38870074-038CE768-125D-4DE4-B5E0-0F72D80C0CCAQ38871499-2F9FB6F7-CE42-453B-955E-549457966063Q38907925-FE49A07C-6DA9-4322-9193-FDC3D5F609D1Q38930244-9231C0F7-E90D-4D3A-9C2E-9633A94AB558Q38947116-879C94E9-3EFF-4847-94FB-3BFE51EB05A4Q39043417-CB35883E-2903-4B54-BEC2-B8E1CB2B4001Q39178065-6C31FA6E-1DA7-44BB-A2C2-E556C759913FQ39224315-95B0BEC0-7C12-4570-9F4F-603A556172FD
P2860
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@ast
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@en
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@nl
type
label
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@ast
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@en
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@nl
prefLabel
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@ast
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@en
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@nl
P2093
P50
P3181
P356
P1476
Immune Checkpoint Inhibition f ...... ic Mismatch Repair Deficiency.
@en
P2093
Adam Shlien
Alyssa Reddy
Andrew Dodgshun
Brittany B Campbell
Carol Durno
Cynthia E Hawkins
Daniele Merico
Gary Mason
Gideon Rechavi
Jeffrey Atkinson
P304
P3181
P356
10.1200/JCO.2016.66.6552
P407
P577
2016-07-01T00:00:00Z